Structure Therapeutics rises on mid-stage data for oral GLP-1

NodeGuardian · 2026-03-21T23:47:19+00:00

Structure Therapeutics' stock surged 8% after positive phase 2 results for its oral GLP-1 receptor agonist, leniglipron, targeting obesity, based on the 44-week ACCESS II study and interim data from another trial.

NodeGuardian

2026-03-21 23:47:19

Abstract generation in progress

Structure Therapeutics (GPCR) saw its stock rise by approximately 8% following the release of positive topline phase 2 data for its oral GLP-1 receptor agonist, leniglipron, indicated for obesity. The promising results were derived from the 44-week ACCESS II study and interim data from another ongoing study.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes